Effect of Video Education on Patients' Knowledge and Attitudes of Privacy in Prenatal Genetics

Study Overview
=================
Brief Summary
-----------------
The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes.

Detailed Description
-----------------
The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes. Pregnant women undergoing specialized fetal anatomic ultrasound surveys at Women and Infants' maternal fetal medicine prenatal diagnostic imaging centers will be recruited to participate. Volunteers will be randomized to receive either standard education about prenatal genetic testing or standard education plus additional education about federal genetic privacy protections. Next, the participants view the educational materials to which they were randomized. Finally, all volunteers will take the same survey, which will assess baseline demographic variables as well as their knowledge of and attitudes toward broad sharing of data obtained from prenatal genetic testing. Once finished with the survey, volunteers will have completed their participation in this study.

Official Title
-----------------
Effect of Video Education on Patients' Knowledge and Attitudes of Privacy in Prenatal Genetics

Conditions
-----------------
Aneuploidy, Genetic Disease, Pregnancy Related

Intervention / Treatment
-----------------
* Behavioral: Enhanced (experimental) education
* Behavioral: Standard (control) education.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant patients undergoing a scheduled L2 ultrasound at the Women and Infants Prenatal Diagnosis Center (PDC) Singleton pregnancies English speaking Results available from cell-free DNA screening for this pregnancy Exclusion Criteria: Prior L2 ultrasound at the PDC during the current pregnancy (to avoid test-retest or multiple approach) Prior participation in this study Gestational age <17'0 weeks or >23'6 weeks Suboptimally dated pregnancies (i.e. dated by ultrasound after 22 weeks gestation) Unscheduled / add-on L2 ultrasounds

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Control<br>The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit. | Behavioral: Standard (control) education.<br>* See arm description.<br>|
| Experimental: Experimental<br>The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA). | Behavioral: Enhanced (experimental) education<br>* See arm description.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge about broad sharing of genetic data for non-clinical research purposes | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient knowledge about the potential sharing of their genetic data for non-clinical research purposes? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Acceptability of broad sharing of genetic data for non-clinical research purposes | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of laboratory-initiated sharing of their de-identified genetic data for non-clinical purposes? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptability of retention of genetic data for non-clinical purposes | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of retaining their de-identified genetic data to potentially use it for non-clinical purposes? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Acceptability of use of genetic data for non-clinical purposes | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of using their de-identified genetic data for non-clinical purposes such as research and development? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Knowledge and understanding of aneuploidy screening and results | Are patients aware that they underwent aneuploidy screening with cell-free fetal DNA (cfDNA)? Are they aware of their results? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Knowledge and understanding of carrier testing and results | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patients aware that they underwent carrier testing? Are they aware of their results? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Acceptability of retention, use, and broad sharing of fetal genetic data for non-clinical research purposes | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Assess maternal acceptance of each of these outcomes. Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Maternal rationale for pursuing cfDNA | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What prompted patient to pursue cfDNA testing? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Maternal knowledge of different commercial cfDNA providers | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patents who have undergone cfDNA testing aware that multiple companies offer this service? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Maternal knowledge pertaining to Down Syndrome and the genetics of trisomies. | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening and are participating in this study understand these topics? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 
| Maternal perceptions of the de-identifiability of genetic data | Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening believe that deidentified genetic information is not re-identifiable? Outcome will be measured on the Likert scale. | This outcome will be assessed immediately after exposure to education (day 0) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetic privacy, Aneuploidy screening, Pregnancy, Data use, Data sharing, Protected health information